Ahmed Emad Ibrahim Hamouda, Peter Ettmayer, Gregor Eisenwort, Satu Mustjoki, Giulia Rossetti, Kristina Feldberg, Jens Panse, Frank Hilberg, Anne Kaiser, Marcelo A. S. Toledo, Karoline V. Gleixner, Malrun Gatz, Peter Valent, Angela Maurer, Andreas Reiter, Nicolas Chatain, Herdit M. Schüler, Wolfgang Wagner, Olli Dufva, Riccardo Guareschi, Tim H. Brümmendorf, Roman Goetzke, Martin Zenke, Steffen Koschmieder, Mohamad Jawhar, Frederick Kluge, Till Braunschweig, Antonio Sechi, Stephanie Sontag, TRIMM - Translational Immunology Research Program, Doctoral Programme in Clinical Research, Department of Clinical Chemistry and Hematology, Digital Precision Cancer Medicine (iCAN), HUS Comprehensive Cancer Center, Doctoral Programme in Drug Research, Doctoral Programme in Biomedicine, and Research Programs Unit
The KIT D816V mutation is found in >80% of patients with systemic mastocytosis (SM) and is key to neoplastic mast cell (MC) expansion and accumulation in affected organs. Therefore, KIT D816V represents a prime therapeutic target for SM. Here, we generated a panel of patient-specific KIT D816V induced pluripotent stem cells (iPSCs) from patients with aggressive SM and mast cell leukemia to develop a patient-specific SM disease model for mechanistic and drug-discovery studies. KIT D816V iPSCs differentiated into neoplastic hematopoietic progenitor cells and MCs with patient-specific phenotypic features, thereby reflecting the heterogeneity of the disease. CRISPR/Cas9n-engineered KIT D816V human embryonic stem cells (ESCs), when differentiated into hematopoietic cells, recapitulated the phenotype observed for KIT D816V iPSC hematopoiesis. KIT D816V causes constitutive activation of the KIT tyrosine kinase receptor, and we exploited our iPSCs and ESCs to investigate new tyrosine kinase inhibitors targeting KIT D816V. Our study identified nintedanib, a US Food and Drug Administration–approved angiokinase inhibitor that targets vascular endothelial growth factor receptor, platelet-derived growth factor receptor, and fibroblast growth factor receptor, as a novel KIT D816V inhibitor. Nintedanib selectively reduced the viability of iPSC-derived KIT D816V hematopoietic progenitor cells and MCs in the nanomolar range. Nintedanib was also active on primary samples of KIT D816V SM patients. Molecular docking studies show that nintedanib binds to the adenosine triphosphate binding pocket of inactive KIT D816V. Our results suggest nintedanib as a new drug candidate for KIT D816V–targeted therapy of advanced SM.